Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Growth Is Accelerating As Industry Transformation Continues
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
The minimally invasive glaucoma surgery (MIGS) devices market is undergoing rapid expansion, driven by advancements in surgical techniques and growing awareness of eye health. As glaucoma continues to affect millions worldwide, the demand for less invasive and more effective treatment options has never been higher. Let’s explore the market’s current size, key growth drivers, leading players, and emerging trends shaping the future of MIGS devices.
Strong Growth Trajectory in the Minimally Invasive Glaucoma Surgery Devices Market
The MIGS devices market has seen remarkable growth in recent years. It is projected to rise from $0.89 billion in 2025 to $1.14 billion in 2026, representing a compound annual growth rate (CAGR) of 28.1%. Several factors contributed to this growth, including the rising prevalence of glaucoma, an aging global population, the limitations of traditional glaucoma surgeries, greater awareness about vision preservation, and increasing rates of cataract surgeries. Looking ahead, the market is expected to expand even further, reaching $2.79 billion by 2030 with a CAGR of 24.9%. This forecasted growth is supported by an expanding pool of glaucoma patients, wider acceptance of minimally invasive procedures, increasing demand for outpatient eye surgeries, a stronger focus on patients’ quality of life, and the growing availability of specialized eye care clinics.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15863&type=smp
Key Factors Supporting Growth in the MIGS Devices Market
The rising incidence of eye disorders plays a significant role in driving the demand for MIGS devices. Eye conditions, including glaucoma, are becoming more common due to lifestyle changes, environmental factors, and an aging population worldwide. MIGS devices are designed to manage these diseases by effectively lowering intraocular pressure (IOP), which is critical in preventing the progression of glaucoma. For instance, according to the National Eye Institute, approximately 2.2 million Americans will be blind or partially blind by 2030, underscoring the urgent need for improved treatment options like MIGS.
Expanding Patient Acceptance and Technology Adoption in MIGS
Another key driver is the growing acceptance of minimally invasive surgical options among patients and healthcare providers. These procedures offer benefits such as quicker recovery times, reduced complications, and suitability for outpatient settings. Additionally, combining MIGS with cataract surgery has become increasingly popular, allowing for dual treatment in one surgical session. This integration supports the market’s expansion by appealing to a broader patient base seeking safer and more efficient eye care.
Access The Complete Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Report:
How the MIGS Devices Market Is Categorized for In-Depth Analysis
This market is segmented into several categories to better understand its dynamics:
1) By Product Type: Trabecular Micro-Stents, Subconjunctival Micro-Shunts, Suprachoroidal Stents, and Canaloplasty & Schlemm’s Canal Devices
2) By Surgical Approach: MIGS performed alongside cataract surgery, and Stand-Alone MIGS procedures
3) By Target Anatomical Pathway: Trabecular Meshwork, Schlemm’s Canal, Suprachoroidal Space, and Subconjunctival Space
4) By Procedure Type: Ab-Interno MIGS and Ab-Externo MIGS
5) By End User: Ophthalmology Clinics, Ambulatory Surgery Centers (ASCs), and Specialized Eye Hospitals
The report further breaks down subsegments such as single-lumen and multi-lumen trabecular micro-stents, various types of subconjunctival micro-shunts, passive and flow-regulated suprachoroidal stents, and different canaloplasty devices including implant-free systems.
Innovations Transforming the Minimally Invasive Glaucoma Surgery Devices Market
Leading companies in the MIGS space are focusing on breakthroughs like sustained-release drug-delivery implants to replace conventional eye-drop treatments. These implants provide continuous medication delivery, improving patient adherence and treatment effectiveness by reducing the need for frequent dosing. A notable example is the February 2024 launch by Celanese Corporation in partnership with Glaukos of the iDose® TR Implant, which uses Celanese’s VitalDose® Ethylene Vinyl Acetate platform. This device delivers travoprost directly inside the eye over several months, offering a minimally invasive alternative to daily eye drops and enhancing long-term control of intraocular pressure.
Competitive Landscape of the MIGS Devices Industry
The minimally invasive glaucoma surgery devices market is populated by several prominent companies, including Glaukos Corporation, Sight Sciences Inc., Alcon Inc., Johnson & Johnson Vision Care Inc., Bausch & Lomb Incorporated, Carl Zeiss Meditec AG, Nova Eye Medical Limited, iSTAR Medical SA, New World Medical Inc., MicroSurgical Technology Inc., ASICO LLC, Ziemer Ophthalmic Systems AG, Ellex Medical Lasers Ltd., Lumenis Ltd., Iridex Corporation, Katena Products Inc., Oertli Instrumente AG, Sifi S.p.A., Aquesys Inc., and Beaver-Visitec International. These players compete through continuous innovation and strategic partnerships to maintain market leadership.
Geographic Highlights Demonstrate Market Leaders and Emerging Regions
In 2025, North America held the largest share of the MIGS devices market, benefiting from high healthcare expenditure and advanced ophthalmic infrastructure. However, the Asia-Pacific region is anticipated to exhibit the fastest growth during the forecast period, driven by increasing healthcare investments, rising awareness of glaucoma treatment options, and expanding access to specialized eye care across countries such as China, India, and Japan. Other important markets include South East Asia, Western and Eastern Europe, South America, the Middle East, and Africa, providing a comprehensive global perspective on the market’s development.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
